Quality Improvement Education Grants
We support Quality Improvement Education (QIE) grants that educate healthcare professionals in the latest medical technology and techniques aligned to National Quality Priorities.
Specific QIE initiatives will focus on demonstrating improvement of patient care within healthcare organizations and their impact will be disseminated via publications or real-world data reporting.
Types of QIE Initiatives
QIE initiatives include interventions designed independent of Boehringer Ingelheim’s input or involvement and may or may not include education that is certified for healthcare professionals. For initiatives that provide a form of certified education (CE), we cannot provide any resources or expertise into the development or execution of the educational interventions to ensure that the Independent Medical Education (IME) component remains free from Boehringer Ingelheim influence.
Boehringer Ingelheim also provides support for collaborative QIE opportunities where Boehringer Ingelheim may partner with a professional or medical association or society. Involvement may include dissemination of a Boehringer Ingelheim Request for Proposal to their members and/or assembling a final external review committee for funding decisions.
Apply for Funding
Visit our Grants and Funding Portal
to submit a new application now.
Fibrosing Interstitial Lung Diseases (ILDs)
Improve the quality of patient care by ensuring understanding of the clinical profiles of SGLT2 inhibitors and/or other relevant interventions, cardiovascular/renal outcome trial results, and their clinical implications within current management landscape with emphasis on these areas:
- Provider, patient, and care partner education
- Treatment guidelines/recommendations
- Coordination of care
- Increase the healthcare team’s implementation of risk factor guided screening and monitoring guidelines to encourage earlier identification of fibrosing ILDs (i.e., IPF, PPF, SARD-ILD), prompt treatment, or referral to appropriate specialists or specialty centers.
- Improve the healthcare team’s utilization of guideline recommended screening and monitoring methods including HRCT and pulmonary function testing.
- Increase guideline based routine assessments in patients with or at risk for fibrosing ILDs (i.e., IPF, PPF, SARD-ILD) to promptly identify lung involvement, acute exacerbations, and disease progression.
- Identify significant barriers that contribute to healthcare disparities impacting fibrosing ILD (i.e., IPF, PPF, SARD-ILD) patients with a goal to enhance early disease detection.
Proposals in the following areas are not being considered:
Biosimilars
